

Bid Evaluation Report (BER) Technical only for RBC FY 2023-24
Regional Blood Center, Peshawar,
Health Department, Khyber Pakhtunkhwa.

All concerned to please note in the public interest that:

1. This BER is shared in compliance to Rule 45 of KPPRA Rules 2014 and to serve the purpose of ensuring more transparency and equity in the bidding process by providing equal opportunities to all concerned bidders to have access to information related to their bids and fair competition; and
- in light of Khyber Pakhtunkhwa Public Regulatory Authority letter No. PK-PPRA/GRR/Appeal/209 of 2023/1594 dated 22.02.2024 regarding appeal under the Khyber Pakhtunkhwa Public Procurement Grievance Redressal Rules, 2017 titled M/S Hooraa Pharma VS Manager, Regional Blood Centre, Peshawar, The same was reevaluated and being shared accordingly.
2. This list will be kept on this website till 02:00 p.m. on 07th March 2024 (Thursday); and
3. This list is being shared to eliminate the possibility of any error in terms of figures or words related to quoted items in the bids; and
4. It is stressed to please note that this list is in no way a final document to be used as an evidence or argument for selection of products for rate contracting from the lowest bidder or award or justification of supply contract / order to the selected bidder by the procuring agency; and
5. All possible efforts have been made to reduce human errors and omissions but still inadvertent errors and omissions may possibly be expected in this list. All the bidders participating in this bidding competition are expected and requested to thoroughly examine this document and point out any error or omission in terms of names, strength, quantity, total marks obtained, etc. of products or any other details which have been entered into this list.
6. Any feedback related to errors and omissions regarding technical evaluation must reach the office of Manager Regional Blood Center, Hayatabad Peshawar not later than 02.00 p.m. on Thursday, 06th March 2024, in written form duly signed and attested by the responsible relevant person of the firm; and
7. This list is only meant to rectify / correct the mistakes, if any that might have occurred during the data entry process for the already submitted bids to facilitate final bidding competition to be held shortly by the Procurement Committee RBC. Therefore, no new or revised data, information, price, claim, explanation, etc. will be entertained for entering into and / or in any way affecting and / or manipulating the final list for the bidding competition; and
8. Any comments, feedback etc. received after the above mentioned cutoff time and date (Para-5 above) will not be considered and the so finalized list will be placed before the Procurement Committee RBC for finalizing the competition in the best public interest.
9. The Procurement committee, at its discretion as per KPPRA rules may decide select or otherwise any item mentioned in this document for the current bidding competition 2023-24.

| Supplier | Make | Certification | Product Information | | Total Technical Score | Remarks |
|------------------------|---------------------------|---------------|----------------------|----------------------|-----------------------|---------------------------|
| | | | Generic Name of Item | Trade Name | 70 | |
| SECTION-D (CLIA KITS) | | | | | | |
| M/S Abbott Diagnostics | Abbott,Germany | US FDA+EC | Syphilis CLIA Kit | Architect | 0 | Technically Nonresponsive |
| M/S Abbott Diagnostics | Abbott,Germany | US FDA+EC | Hbs Ag CLIA Kit | Architect | 0 | Technically Nonresponsive |
| M/S Abbott Diagnostics | Abbott,Germany | US FDA+EC | anti HCV CLIA kit | Architect | 0 | Technically Nonresponsive |
| M/S Abbott Diagnostics | Abbott,Germany | US FDA+EC | HIV CLIA kit | Architect | 0 | Technically Nonresponsive |
| M/S Roche Pakistan | Roche Germany | US FDA+EC | Syphilis CLIA Kit | Elesys Syphilis | 0 | Technically Nonresponsive |
| M/S Roche Pakistan | Roche Germany | US-FDA + EC | Hbs Ag CLIA Kit | Elesys Hbs Ag Gene 2 | 0 | Technically Nonresponsive |
| M/S Roche Pakistan | Roche Germany | US-FDA + CE | anti HCV CLIA kit | Elesys Anti-HCV II | 0 | Technically Nonresponsive |
| M/S Roche Pakistan | Roche Germany | US-FDA + CE | HIV CLIA kit | Elesys Combi PT | 0 | Technically Nonresponsive |
| M/S Hooraa Pharma | Seimens Health Ineers USA | | Syphilis CLIA kit | Ateilla IM HBsII200T | 0 | Technically Nonresponsive |
| M/S Hooraa Pharma | Seimens Health Ineers USA | | HBsAg CLIA kit | Ateilla IM HBsII200T | 0 | Technically Nonresponsive |
| M/S Hooraa Pharma | Seimens Health Ineers USA | | HIV CLIA kit | Ateilla IM HBsII200T | 0 | Technically Nonresponsive |
| M/S Hooraa Pharma | Seimens Health Ineers USA | | Anti HCV CLIA kit | Ateilla IM HBsII200T | 0 | Technically Nonresponsive |
| M/S Sind Medical Store | DiaSorin Italy | US FDA+CE | Syphilis CLIA Kit | Liaison XL | 64 | Responsive |
| M/S Sind Medical Store | DiaSorin Italy | US FDA+CE | Hbs Ag CLIA Kit | Liaison XL | 64 | Responsive |
| M/S Sind Medical Store | DiaSorin Italy | US FDA+CE | anti HCV CLIA kit | Liaison XL | 64 | Responsive |
| M/S Sind Medical Store | DiaSorin Italy | US FDA+CE | HIV CLIA kit | Liaison XL | 64 | Responsive |